Literature DB >> 28844613

Percutaneous thermal ablation of lung tumors - Radiofrequency, microwave and cryotherapy: Where are we going?

J Palussière1, V Catena2, X Buy2.   

Abstract

Main indications of percutaneous pulmonary thermal ablation are early stage non-small cell lung carcinoma (NSCLC) for patients who are not amenable to surgery and slow-evolving localized metastatic disease, either spontaneous or following a general treatment. Radiofrequency ablation (RFA) is the most evaluated technique. This technique offers a local control rate ranging between 80 and 90% for tumors <3cm in diameter. Other more recently used ablation techniques such as microwaves and cryotherapy could overcome some limitations of RFA. One common characteristic of these techniques is an excellent tolerance with very few complications. This article reviews the differences between these techniques when applied to lung tumors, indications, results and complications. Future potential associations with immunotherapy will be discussed.
Copyright © 2017. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Cryotherapy; Lung cancer; Microwave ablation; Percutaneous treatment; Radiofrequency ablation

Mesh:

Year:  2017        PMID: 28844613     DOI: 10.1016/j.diii.2017.07.003

Source DB:  PubMed          Journal:  Diagn Interv Imaging        ISSN: 2211-5684            Impact factor:   4.026


  25 in total

Review 1.  The role of radiology in the evaluation of the immunotherapy efficacy.

Authors:  Marco Calandri; Federica Solitro; Valeria Angelino; Federica Moretti; Andrea Veltri
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

2.  Effect of changes in lung physical properties on microwave ablation zone during respiration.

Authors:  Defu Yang; Miao Cao
Journal:  Biomed Eng Lett       Date:  2020-01-07

3.  A comparative analysis of thermal ablation techniques in the treatment of primary and secondary lung tumors: a single-center experience.

Authors:  Rosario Francesco Grasso; Caterina Bernetti; Giuseppina Pacella; Carlo Altomare; Gennaro Castiello; Flavio Andresciani; Marina Sarli; Bruno Beomonte Zobel; Eliodoro Faiella
Journal:  Radiol Med       Date:  2022-06-14       Impact factor: 6.313

Review 4.  The Latest on Lung Ablation.

Authors:  Peyton Cramer; Bradley B Pua
Journal:  Semin Intervent Radiol       Date:  2022-08-31       Impact factor: 1.780

5.  Microwave ablation for non-small cell lung cancer with synchronous solitary extracranial metastasis.

Authors:  Yang Ni; Xin Ye; Xia Yang; Guanghui Huang; Wenhong Li; Jiao Wang; Xiaoying Han; Zhigang Wei; Min Meng; Zhigeng Zou
Journal:  J Cancer Res Clin Oncol       Date:  2020-03-07       Impact factor: 4.553

6.  Comparing cryoablation and microwave ablation for the treatment of patients with stage IIIB/IV non-small cell lung cancer.

Authors:  Sushant Kumar Das; Ya-Yong Huang; Bing Li; Xiao Xuan Yu; Ru Hui Xiao; Han Feng Yang
Journal:  Oncol Lett       Date:  2019-11-25       Impact factor: 2.967

Review 7.  Recent advances in early stage lung cancer.

Authors:  Javier Luna; Amalia Sotoca; Pablo Fernández; Celia Miralles; Aurora Rodríguez
Journal:  J Clin Transl Res       Date:  2021-04-06

8.  Efficacy and safety of thermal ablation of lung malignancies: A Network meta-analysis.

Authors:  Binghu Jiang; Morgan A Mcclure; Tianming Chen; Shilin Chen
Journal:  Ann Thorac Med       Date:  2018 Oct-Dec       Impact factor: 2.219

Review 9.  Optimizing Loco Regional Management of Oligometastatic Colorectal Cancer: Technical Aspects and Biomarkers, Two Sides of the Same Coin.

Authors:  Giovanni Mauri; Lorenzo Monfardini; Andrea Garnero; Maria Giulia Zampino; Franco Orsi; Paolo Della Vigna; Guido Bonomo; Gianluca Maria Varano; Marco Busso; Carlo Gazzera; Paolo Fonio; Andrea Veltri; Marco Calandri
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

Review 10.  Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT.

Authors:  Meritxell Molla; Julen Fernandez-Plana; Santiago Albiol; Constantino Fondevila; Ivan Vollmer; Carla Cases; Angeles Garcia-Criado; Jaume Capdevila; Carles Conill; Yliam Fundora; Carlos Fernandez-Martos; Estela Pineda
Journal:  J Clin Med       Date:  2021-05-14       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.